【レポートの概要(一部)】
1. Report Overview
1.1 Global RNAi Therapies Market Overview
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to RNAi Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Overview of RNA: From DNA to Proteins, and Beyond
2.2.1 The Functions of RNA
2.2.2 The Discovery of RNA Interference
2.3 RNAi Timeline: From Discovery to Human Trials
2.4 RNAi: Repurposing a Natural Cellular Gene-Silencing Process
2.4.1 siRNA: Application in Genetic Diseases
2.4.2 miRNA: Natural Gene Expression Regulators
2.5 Development of RNAi Therapies
2.5.1 The Delivery Approach: Exogenous Introduction of siRNA
2.5.2 ddRNAi: Stable Expression of RNAi Inducers
2.5.2.1 shRNA: Employing Viral Vectors
2.6 Ribopharma AG: The First Company to Specialise in RNAi Therapeutics
2.7 Phases of Clinical Trials
2.8 Scope of This Report
2.8.1 Products Excluded from This Report
2.9 Currency Exchange Rates in This Report
3. Leading Therapeutic Applications for RNAi
3.1 Therapeutic Areas Driving the RNAi Therapeutics Market to 2025
3.2 Infectious Diseases and Cancer Account for Most Pipeline Therapies in 2015
3.3 Infectious Diseases – Protecting and Saving Lives through Medical Progress
3.3.1 Viral Hepatitis
3.3.1.1 Hepatitis B and C
3.3.1.2 Prospects for RNAi in Hepatitis B and C
3.3.2 Prospects for RNAi in HIV Infection
3.4 Cancer: Great Scope for New Therapies
3.5 Ophthalmic Diseases – Limited Opportunity for Developers?
3.5.1 RNAi for AMD: No Clinical Candidates in 2015
3.5.2 RNAi for Glaucoma: Limited Role in Treatment?
3.6 Lung Diseases and Respiratory Disorders – Life-Improving Treatments
3.6.1 Respiratory Syncytial Virus Infection
3.7 Kidney Disease – Investigations to Treat the Urinary System
3.7.1 Delayed Graft Function (DGF)
4. RNAi Therapies: World Market 2015-2025
4.1 The World RNAi Therapies Market in 2014
4.2 RNAi Therapies Market Segmentation, 2014
4.3 World RNAi Therapies Market: Sales Forecast 2015-2025
4.4 World RNAi Therapies Market: Drivers and Restraints 2015-2025
5. Leading Regional Markets 2015-2025
5.1 Scope and Limitations
5.2 World RNAi Therapies Market: Regional Forecast 2015-2025
5.3 How Will Regional Market Shares Change to 2025?
5.4 US RNAi Therapies Market 2015-2025
5.4.1 FDA Approval of Kynamro Improves RNAi Prospects
5.5 EU5 RNAi Therapies Market 2015-2025
5.5.1 RNAi Prospects in Leading EU Markets
5.6 Asia-Pacific RNAi Therapies Market 2015-2025
5.6.1 Prospects for RNAi Therapies in Japan
5.6.2 China Steps Up Efforts in RNAi Drug Development
5.6.3 India: Company Collaborations to Stimulate Interest in RNAi
5.7 Latin American RNAi Therapies Market 2015-2025
5.8 The RNAi Therapies Market in the Rest of the World 2015-2025
6. RNAi Therapies: Leading Companies 2015-2025
6.1 Alnylam Pharmaceuticals
6.1.1 RNAi Therapeutic Pipeline: Strong Portfolio
6.1.1.1 Genetic Medicine STAr
6.1.1.2 Cardio-metabolic Disease STAr
6.1.1.3 Hepatic Infectious Disease STAr
6.1.1.4 Other Pipeline Products: Development on Hold
6.1.1.5 Other Pipeline Products: ALN-RSV01 for RSV Infection
6.1.1.6 Other Pipeline Products: ALN-VSP02 for Liver Cancers
6.1.2 Sales and Recent Performance
6.1.3 Recent Developments
6.1.3.1 Alnylam Files Trade Secret Misappropriation Suit Against Dicerna
6.1.3.2 Alnylam Enters Strategic Alliance with Genzyme (Sanofi)
6.1.3.3 Other Alliances with Leading Companies
6.1.3.4 Acquisition of Sirna Therapeutics
6.1.3.5 Contract Manufacturing of siRNAs by Tekmira Pharmaceuticals
6.2 Arrowhead Research
6.2.1 RNAi Therapeutic Pipeline: Targeting Hepatitis B and Alpha-1 Antitrypsin Deficiency
6.2.2 Sales and Recent Performance
6.2.3 Recent Developments
6.2.3.1 Roche Acquisition Strengthens Company’s Market Position
6.2.3.2 Arrowhead Acquires Novartis’ RNAi Assets
6.3 Benitec Biopharma
6.3.1 RNAi Therapeutic Pipeline
6.3.2 Sales and Recent Performance
6.3.3 Recent Developments
6.3.3.1 ddRNAi Patent Maintained by Australia’s CSIRO
6.3.3.2 Agreement with Omnia Biologics
6.4 Gradalis Incorporated
6.4.1 RNAi Therapeutic Pipeline: Advancing Gradalis for Cancer
6.5 Quark Pharmaceuticals
6.5.1 RNAi Therapeutic Pipeline: A Broad siRNA Portfolio in Clinical Development
6.5.1.1 Preclinical Pipeline: Collaboration with Nitto Denko
6.5.2 Recent Developments
6.5.2.1 Quark Partners with Big Pharma to Develop RNAi Therapies
6.5.2.2 RiboQuark: Joint Venture with Suzhou Ribo Life Science
6.6 Roche Innovation Center Copenhagen
6.6.1 RNAi Therapeutic Pipeline: Potential in Locked Nucleic Acid Platform?
6.6.1.1 Former Santaris Pipeline Candidates
6.6.2 Recent Developments
6.6.2.1 Targeting Rare Genetic Diseases through Alliance with Shire
6.6.2.2 Roche and Isis Pharmaceuticals to Settle Patent Lawsuit?
6.7 RXi Pharmaceuticals
6.7.1 RNAi Therapeutic Pipeline: Lead Candidate RXI-109 Prevents Scar Formation
6.7.2 Sales and Recent Performance
6.7.3 Recent Developments
6.7.3.1 Early Distribution Agreement with Ethicor
6.7.3.2 Acquisition of RNAi Assets from OPKO Health
6.8 Silence Therapeutics
6.8.1 RNAi Therapeutic Pipeline: Lead Candidate Atu027 Completed Phase 2
6.8.1.1 Multiple Delivery Technologies Offers Promise
6.8.2 Sales and Recent Performance
6.8.3 Recent Developments
6.8.3.1 Partnerships for Silence Therapeutics’ RNAi Platform
6.8.3.2 Silence Therapeutics Wins European Patent Office Appeal Covering RNAi Trigger Modification
6.9 Silenseed
6.9.1 RNAi Therapeutic Pipeline
6.9.2 Recent Developments
6.9.2.1 Silenseed IPO Filed in 2014
6.10 Sylentis
6.10.1 RNAi Therapeutic Pipeline: First Spanish Company to Conduct Clinical Trials of an RNAi Drug
6.10.2 Recent Developments
6.10.2.1 Zeltia Subsidiary PharmaMar May Merge with Its Parent Company
6.11 Tekmira Pharmaceuticals
6.11.1 RNAi Therapeutic Pipeline: Focusing on Cancer and Ebola
6.11.2 Sales and Recent Performance
6.11.3 Recent Developments
6.11.3.1 Out-Licensing of LNP Technology Adding Extra Revenue
6.11.3.2 Tekmira Merges with OnCore
6.12 Other Companies of Interest
7. RNAi Therapies: Development Pipeline 2015-2025
7.1 The RNAi Therapies Pipeline
7.2 RNAi Therapies: Phase 3 Pipeline
7.2.1 ALN-TTR02 (patisiran, Alnylam)
7.2.1.1 ALN-TTR02: Sales Forecast 2015-2025
7.2.2 ALN-TTRsc (revusiran, Alnylam)
7.2.2.1 ALN-TTRsc: Sales Forecast 2015-2025
7.2.3 Vigil (Cancer Immunotherapy, Gradalis Incorporated)
7.2.3.1 Vigil: Sales Forecast 2015-2025
7.3 RNAi Therapies: Phase 2 Pipeline
7.3.1 ALN-RSV01 (targeting RSV nucleocapsid, Alnylam)
7.3.2 ARC-520 (targeting conserved regions of HBV, Arrowhead)
7.3.2.1 ARC-520 Clinical Trial Results and Analysis
7.3.2.2 ARC-520: Sales Forecast 2015-2025
7.3.3 Atu027 (targeting PKN3, Silence Therapeutics)
7.3.3.1 Atu027: Sales Forecast 2015-2025
7.3.4 PF-655 (RTP801I-14) (targeting RTP801, Quark)
7.3.4.1 PF-655: Sales Forecast 2015-2025
7.3.5 QPI-1002 (I5NP) (targeting p53, Quark)
7.3.5.1 QPI-1002: Sales Forecast 2015-2025
7.3.6 RXI-109 (targeting CTGF, RXi Pharmaceuticals)
7.3.6.1 RXI-109: Sales Forecast 2015-2025
7.3.7 siG12D-LODER (targeting KRAS, Silenseed)
7.3.7.1 siG12D-LODER: Sales Forecast 2015-2025
7.3.8 SPC3649 (miravirsen) (targeting miR-122, Roche)
7.3.8.1 SPC3649: Sales Forecast 2015-2025
7.3.9 SYL040012 (targeting ADRB2, Sylentis Pharmaceuticals)
7.3.9.1 SYL040012: Sales Forecast 2015-2025
7.3.10 SYL1001 (targeting TRPV1, Sylentis Pharmaceuticals)
7.3.11 TKM-PLK1 Products (targeting PLK1, Tekmira)
7.3.12 TT-034 (targeting Hepatitis C Virus, Benitec Biopharma)
7.4 RNAi Therapies: Phase 1 Pipeline
7.5 RNAi Therapies: Preclinical Pipeline
8. Qualitative Analysis of the RNAi Therapies Market 2015-2025
8.1 SWOT Analysis of the RNAi Therapies Market
8.2 Strengths
8.2.1 A Highly Specific and Selective Therapy
8.2.2 Lower Therapeutic Dosages
8.2.3 Shorter Lead Identification Times
8.2.4 Manufacturing Synthetic RNAs: Cost-Effective and Easier Than for Other Biologics
8.3 Weaknesses
8.3.1 Challenges of Systemic Delivery of RNAi
8.3.1.1 Poor Cellular Uptake and Low Stability of siRNAs in Blood Serum
8.3.1.2 Systemic and Targeted Delivery of RNAi-based Drug Candidates
8.3.1.3 Industry’s Approach to Overcome the Introduction Challenges
8.3.2 Off-target Binding, Immune Response and Oversaturation Elevates Risk of Side Effects
8.4 Opportunities
8.4.1 Treating Multifactorial Diseases: A Revolutionary Therapeutic?
8.4.2 Combination Therapy with Antisense Technology or Aptamers?
8.4.2.1 Antisense Technology: First-to-Market Advantage
8.4.2.2 Aptamers: Offering Advantages over Antibodies
8.4.3 The Untapped Potential of mRNA
8.5 Threats
8.5.1 Novel Class of Treatment May Have Prolonged Approval Process
8.5.2 Large Scale Production of RNAs: A Potential Threat to Commercialisation?
8.5.3 Advances in Alternative Gene-Silencing Approaches Such As CRISPRs
8.6 STEP Analysis of the RNAi Therapies Market
8.6.1 Social Factors
8.6.2 Technological Factors
8.6.3 Economic Factors
8.6.4 Political Factors
9. Research Interviews
9.1 Interview with Mr Joseph Payne, CEO of Arcturus Therapeutics, San Diego, California
9.1.1 Arcturus Therapeutics’ RNAi Therapies Pipeline
9.1.2The Outlook for TTR-Mediated Disease RNAi Therapies?
9.1.3 Barriers to Market Entry
9.1.4 Opportunities for RNAi Developers
9.1.5 Interest from Big Pharma and Investors
9.1.6 Therapeutic Areas and Targets for RNAi Developers
9.1.7 Other Trends and Developments in RNAi Therapeutics
9.2 Interview with Mr J. Michael French, President and CEO of Marina Biotech, Bothell, Washington
9.2.1 Marina Biotech’s RNAi Pipeline and Platform
9.2.2 Barriers to Market Entry
9.2.3 Opportunities for RNAi Developers
9.2.4 Interest from Big Pharma and Investors
9.2.5 Therapeutic Areas and Targets for RNAi Developers
9.2.6 Other Trends and Developments in RNAi Therapeutics
10. Conclusions
10.1 Market Entry of RNAi Therapies Expected in 2015-2025
10.2 The World RNAi Therapies Market in 2014
10.3 Leading RNAi Therapies Companies
10.4 Leading Regional Markets
10.5 World RNAi Therapies Market Forecast 2015-2025
10.6 RNAi Therapies Late-Stage Pipeline
10.7 The Future of the RNAi Therapies Market: Time for a RNAissance?
11. Glossary
【レポート販売概要】
■ タイトル:RNA干渉(RNAi)治療の世界市場:siRNA、shRNA、ddRNAiアプローチの展望■ 英文:RNAi for Therapeutic Applications: Technology and Market Forecast 2015-2025 : Prospects for siRNAs, shRNAs and ddRNAi Approaches
■ 発行日:2015年6月
■ 調査会社:visiongain
■ 商品コード:VGAIN50611
■ 調査対象地域:グローバル
- 産業ロボットサービスの世界市場2017-2021:マテリアルハンドリング、溶接、組立てラインAbout Industrial Robotics Services Industrial robots can be classified into many types such as material handling, welding, assembling, painting, and for other purposes based on their area of application. Major demand will increase from companies in sectors such as automotive, electrical and electronics, chemicals, food and beverages (F&B), and industrial machinery. Technavio’s analysts forecast th …
- 日本の注射器・注射針市場見通し(~2021)Japan Syringes and Needles Market Outlook to 2021 Summary GlobalData’s new report, "Japan Syringes and Needles Market Outlook to 2021", provides key market data on the Japan Syringes and Needles market. The report provides value, in millions of US dollars, volume (in units) and average price data (in US dollars), within market segments - General Syringes and Specialized Syringes. The report also p …
- 臨床判断支援システムの世界市場予測(~2021):構成要素別(サービス、ソフトウェア)、提供形態別、製品種類別(統合型、独立型)、モデル別、種類別(治療用、診断用)、ユーザー対話性別、用途別The clinical decision support systems market is projected to reach USD 1,519.2 Million by 2021 from USD 856.3 Million in 2016, growing at a CAGR of 12.2%. Factors such as government support and initiatives to drive adoption of HCIT solutions in healthcare, and rising incidence of medication errors are driving the growth of the market. Emerging markets in Asia-Pacific, Middle-East & Africa are like …
- スモールセル5Gネットワークの世界市場:コンポーネント別(ソリューション、サービス)、無線技術別(スタンドアロン、非スタンドアロン)、周波数帯域別(ローバンド、ミッドバンド、ミリ波)、セルタイプ別(フェムトセル、ピコセル、マイクロセル)、アプリケーション別(屋内アプリケーション、屋外アプリケーション)Small cells are low power and short range wireless transmission systems or base stations to cover indoor as well as outdoor applications or small geographical area. They are capable of handling high data rate for individual users and have all the basic characteristics of a conventional base stations. They play a significant role in 5G deployments, to efficiently deliver high speed mobile broadband …
- 自動車用タイヤの世界市場:用途別(トラック・バス、乗用車、2輪車・3輪車、農業用、オフロード車、その他)、地域別予測Global Automotive Tires Market to reach USD 575 billion by 2025. Global Automotive Tires Market valued approximately USD 329 billion in 2016 is anticipated to grow with a healthy growth rate of more than 6.40% over the forecast period 2017-2025. The Global automotive tires market is influenced by several factors which impact the growth of the market. High demand for replacement tires, increasing d …
- クリーンルーム用ロボットの世界市場2016-2020About the Cleanroom Robots Market A cleanroom is a well-maintained environment with minimum levels of environmental pollutants such as aerosols, dusts, chemicals, and microbes. It has strict specifications about the number of particles per cubic meter and regarding particle size. It is typically used for manufacturing products, which require highly sterile and dust-free environment such as semicon …
- 非在来型ガスの世界市場展望2017-2026According to Stratistics MRC, the Global Unconventional Gas market growing at a CAGR of 10.61% during the forecast period. Some of the key factors such as exhaustion of conventional gas reserves and its importance as a primary source of affordable energy for residential, transportation and industrial users, the development of gas from unconventional reservoirs are driving the market growth. Howeve …
- テキスト読み上げ(TTS)教育技術の世界市場2016-2020About Text-To-Speech Education Technology The access to education is gaining mass adoption, largely triggered by e-learning, it also brings into consideration the need to tailor teaching methods. This is essential to create achievable milestones that can meet the objective of providing education to all learners in an equitable manner. As a result, apart from investing in products and services to i …
- Enteric Diseases in the UK 2014: Market Outlook and Emerging OpportunitiesAbout This ReportThis new 322-page report from Venture Planning Group presents detailed analysis of the UK Enteric Diseases market, including sales forecasts and supplier shares for Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio and Yersinia. The report provides test volume and sales projections for Hospitals, Commercial and Public H …
- 世界の感染予防・感染管理市場(2014-2018)About Infection Prevention and Control Infection prevention and control is the most important and significant step in the development and maintenance of products in the Medical Devices, Pharmaceuticals, and Food industries. Sterilization and disinfection protect different products and materials from decaying or being spoiled by microbes. Sterilization and disinfection can be performed by using var …
- [Updated] グローバル戦場管理システム市場予測及び分析2014 – 2019The report provides an in-depth analysis of the global BMS market. It provides information about the current trends in the market with respect to geographies, countries, platforms, and, applications market scenario. It throws light on the current market trends, the drivers, and restraints of this market, and the challenges faced in the market that will impact the growth of this market. It analyzes …
- 自動車用ワイヤーハーネスの世界市場予測(~2021年)“Consumer preference for high-end electronics in automotive gaining pace over the years”The global automotive wiring harness market was estimated to be at USD 42.70 billion in 2016 and projected to reach USD 61.30 billion by 2021, at a CAGR of 7.5%. Increasing complexity in vehicles along with rising intrusion of electronics is driving the demand for automotive wiring harness. As a result, the aut …
- Questar Corporation:石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Questar Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Questar Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for …
- 生分解性プラスチックの世界市場:インサイト、市場機会、市場シェア、市場予測Biodegradable plastics are defined as the ones that can be decomposed in some specified period of time under composting conditions at any industrial facilities. The global biodegradable plastics market is still in its early stage and accounts for less than 1% of the total plastics market., but with continuous R&D activities adopted by the market players, the market is growing at a fast pace. High …
- 手術用スネアの世界市場予測(~2023年)“Increasing awareness on colorectal cancer is expected to drive the overall growth of the surgical snares market.”The surgical snares market size is expected to grow from USD 992 million in 2018 to USD 1255 million by 2023, at a Compound Annual Growth Rate (CAGR) of 4.8% during the forecast period. The surgical snares market is driven by various factors such as the increasing number of colon polyp …